Literature DB >> 10708869

Regulation of blood coagulation.

C T Esmon1.   

Abstract

The protein C anticoagulant pathway converts the coagulation signal generated by thrombin into an anticoagulant response through the activation of protein C by the thrombin-thrombomodulin (TM) complex. The activated protein C (APC) thus formed interacts with protein S to inactivate two critical coagulation cofactors, factors Va and VIIIa, thereby dampening further thrombin generation. The proposed mechanisms by which TM switches the specificity of thrombin include conformational changes in thrombin, blocking access of normal substrates to thrombin and providing a binding site for protein C. The function of protein S appears to be to alter the cleavage site preferences of APC in factor Va, probably by changing the distance of the active site of APC relative to the membrane surface. The clinical relevance of this pathway is now established through the identification of deficient individuals with severe thrombotic complications and through the analysis of families with partial deficiencies in these components and an increased thrombotic tendency. One possible reason that even partial deficiencies are a thrombotic risk is that the function of the pathway can be down-regulated by inflammatory mediators. For instance, clinical studies have shown that the extent to which protein C levels decrease in patients with septic shock is predictive of a negative outcome. Initial clinical studies suggest that supplementation with protein C may be useful in the treatment of acute inflammatory diseases such as sepsis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708869     DOI: 10.1016/s0167-4838(99)00266-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  62 in total

1.  Cardiac intraventricular thrombus in protein C deficiency.

Authors:  K S Nair; A Weerasinghe; M Dahdal; J S Gibbs; J R Anderson
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

2.  So what is critically lacking with coronary atherosclerotic plaques? Perhaps the antithrombotic control.

Authors:  T S Edgington
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 3.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

4.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

5.  Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.

Authors:  Yao-Hsu Yang; Kwan-Ki Hwang; John FitzGerald; Jennifer M Grossman; Mihaela Taylor; Bevra H Hahn; Pojen P Chen
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

6.  Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.

Authors:  Cai-Sheng Lu; Arash A Horizon; Kwan-Ki Hwang; John FitzGerald; Wei-Shiang Lin; Bevra H Hahn; Daniel J Wallace; Allan L Metzger; Michael H Weisman; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2005-12

Review 7.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

8.  The thrombogenicity of human umbilical vein endothelial cell seeded collagen modules.

Authors:  Alison P McGuigan; Michael V Sefton
Journal:  Biomaterials       Date:  2008-03-05       Impact factor: 12.479

Review 9.  Monitoring of endothelial dysfunction in critically ill patients: the role of endothelial progenitor cells.

Authors:  Sushma K Cribbs; Greg S Martin; Mauricio Rojas
Journal:  Curr Opin Crit Care       Date:  2008-06       Impact factor: 3.687

10.  A biologically active surface enzyme assembly that attenuates thrombus formation.

Authors:  Zheng Qu; Sharmila Muthukrishnan; Murali K Urlam; Carolyn A Haller; Sumanas W Jordan; Vivek A Kumar; Ulla M Marzec; Yaseen Elkasabi; Joerg Lahann; Stephen R Hanson; Elliot L Chaikof
Journal:  Adv Funct Mater       Date:  2011-09-26       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.